Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
PTGX 
Protagonist Therapeutics Inc (PTGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: PTGX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $69
1 Year Target Price $69
| 5 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 66.75% | Avg. Invested days 58 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.29B USD | Price to earnings Ratio 67.95 | 1Y Target Price 69 |
Price to earnings Ratio 67.95 | 1Y Target Price 69 | ||
Volume (30-day avg) 10 | Beta 2.25 | 52 Weeks Range 32.50 - 60.60 | Updated Date 07/12/2025 |
52 Weeks Range 32.50 - 60.60 | Updated Date 07/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.04% | Operating Margin (TTM) -68.18% |
Management Effectiveness
Return on Assets (TTM) 2.48% | Return on Equity (TTM) 8.99% |
Valuation
Trailing PE 67.95 | Forward PE 26.39 | Enterprise Value 2722043615 | Price to Sales(TTM) 15.81 |
Enterprise Value 2722043615 | Price to Sales(TTM) 15.81 | ||
Enterprise Value to Revenue 13.1 | Enterprise Value to EBITDA 90.37 | Shares Outstanding 61982000 | Shares Floating 42980147 |
Shares Outstanding 61982000 | Shares Floating 42980147 | ||
Percent Insiders 1.1 | Percent Institutions 108.15 |
Upturn AI SWOT
Protagonist Therapeutics Inc
Company Overview
History and Background
Protagonist Therapeutics, Inc. (PTGX) is a biopharmaceutical company focused on discovering and developing novel peptide-based therapeutics. Founded in 2006, it has advanced several peptide therapeutics into clinical development, targeting unmet needs in areas like inflammatory bowel disease (IBD) and other gastrointestinal conditions.
Core Business Areas
- Research and Development: Focused on discovering and developing novel peptide-based therapeutics.
- Clinical Development: Advancing peptide therapeutics through clinical trials to assess safety and efficacy.
- Partnerships and Licensing: Collaborating with other pharmaceutical companies to develop and commercialize their products.
Leadership and Structure
The leadership team comprises experienced executives in the pharmaceutical and biotechnology industries. The organizational structure includes research, development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Rusfertide: An injectable hepcidin mimetic for the treatment of polycythemia vera (PV). Rusfertide has been approved by the FDA. Competitors include phlebotomy and other cytoreductive therapies. Estimated Revenue in 2024 is not available, but analysts anticipate significant revenue potential upon commercialization.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a focus on developing innovative therapies for various diseases. The market is driven by factors such as aging populations, increasing prevalence of chronic diseases, and advances in biotechnology.
Positioning
Protagonist Therapeutics is positioned as a drug developer and the company is focused on peptide therapeutics. Their competitive advantage lies in their novel peptide platform and pipeline of differentiated assets.
Total Addressable Market (TAM)
The global polycythemia vera market is projected to reach billions of dollars. Protagonist Therapeutics is positioned to capture a share of this market with rusfertide, now approved.
Upturn SWOT Analysis
Strengths
- Novel peptide technology platform
- Pipeline of clinical-stage assets
- Experienced management team
- FDA Approval of Rusfertide
Weaknesses
- Reliance on clinical trial outcomes
- Limited commercialization experience
- Competition from established pharmaceutical companies
- Dependence on partnerships for certain programs
Opportunities
- Expansion of pipeline through internal development and partnerships
- Advancement of clinical programs to regulatory approval
- Increased adoption of peptide therapeutics
- Geographic expansion
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new therapies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- INCY
- CELG
- MYL
Competitive Landscape
Protagonist Therapeutics has innovative assets; however, it is at a disadvantage compared to larger pharmaceutical companies with more resources and established commercial infrastructure. The market share of PTGX is smaller when compared to INCY.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on stock price and market capitalization, requires stock price data analysis.
Future Projections: Future growth projections are unavailable from the provided information.
Recent Initiatives: Recent initiatives include the FDA approval of rusfertide and continued advancement of the pipeline.
Summary
Protagonist Therapeutics is a biopharmaceutical company with a novel peptide technology platform. The recent FDA approval of Rusfertide is a significant achievement. The company's success depends on its ability to successfully commercialize rusfertide and advance its pipeline. Competition from larger pharmaceutical companies and the inherent risks of drug development are key challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Public News Articles
Disclaimers:
The information provided is for informational purposes only and should not be considered as financial advice. Market share estimates are approximate and may vary based on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Protagonist Therapeutics Inc
Exchange NASDAQ | Headquaters Newark, CA, United States | ||
IPO Launch date 2016-08-11 | CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 124 | Website https://www.protagonist-inc.com |
Full time employees 124 | Website https://www.protagonist-inc.com | ||
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.